Draft Guidance on Amlodipine Besylate; Valsartan - Food and Drug ...
Contains Nonbinding Recommendations
Draft Guidance on Amlodipine Besylate; Valsartan
This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.
Active ingredient:
Amlodipine Besylate; Valsartan
Form/Route:
Tablets/Oral
Recommended studies:
3 studies
1. Type of study: Fasting Design: Single-dose, two-way crossover in-vivo Strength: 10 mg (base); 320 mg Subjects: Normal healthy males and females, general population Additional Comments: Females should not be pregnant, and if applicable, should practice abstention or contraception during the study. As an option, due to the relatively long half-life of amlodipine, you may wish to conduct this study using a single dose, two-way parallel design. As an additional option for either the crossover or parallel design, you may wish to truncate the AUC at 72 hours. ____________________________________________________________________
2. Type of study: Fed Design: Single-dose, two-way crossover in-vivo Strength: 10 mg (base); 320 mg Subjects: Normal healthy males and females, general population Additional Comments: Please see comment above. ____________________________________________________________________
3. Type of study: Fasting Design: Single-dose, two-way crossover in-vivo Strength: 10 mg (base); 160 mg Subjects: Normal healthy males and females, general population Additional Comments: Please see comment above.
_____________________________________________________________________________
Analytes to measure (in appropriate biological fluid): Amlodipine and valsartan in plasma.
Bioequivalence based on (90% CI): Amlodipine and valsartan
Waiver request of in-vivo testing: 5 mg (base);160 mg and 5 mg (base);320 mg based on (i) acceptable bioequivalence studies on the 10 mg (base);160 mg and 10 mg (base);320 mg strengths, (ii) acceptable dissolution testing across all strengths, and (iii) proportional similarity in the formulations across all strengths.
Dissolution test method and sampling times:
Please note that a Dissolution Methods Database is available to the public at the OGD website at . Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.
Recommended Aug 2008
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- highlights of prescribing information amlodipine valsartan and
- exforge inn amlodipine valsartan european medicines agency
- µ amlodipine and valsartan tablets usp nf
- amlodipine valsartan and hydrochlorothiazide tablets type of posting
- imprida inn amlodipine besylate valsartan european medicines agency
- sds amlodilpne ans valsartan tablets march 2017 lupin
- amlodipine valsartan and hydrochlorothiazide tablets 5 mg 160 mg 12
- amlodipine valsartan and hydrochlorothiazide tablets
- fda approved patient labeling patient information and valsartan val
- exforge hct amlodipine valsartan hydrochlorothiazide label
Related searches
- amlodipine besylate recall 2019
- food and drug recalls 2019
- amlodipine besylate 5mg recall
- amlodipine besylate recall 2018
- amlodipine besylate 10 mg recall
- amlodipine besylate 10 mg
- amlodipine besylate 5 mg reviews
- amlodipine besylate 5 mg
- amlodipine besylate side effects in women
- amlodipine besylate 10 mg side effects
- amlodipine besylate 2 5 mg recall
- amlodipine besylate side effects complaints